Description

The U.S. multiple sclerosis market is entering a new phase of growth driven by the development of innovative therapeutic platforms. Oral therapies are likely to revolutionize the treatment paradigm of multiple sclerosis by improving dosing and patient compliance.

This research service presents a marketed and pipeline analysis of the U.S. multiple sclerosis market. The purpose of this study is to highlight the current market landscape, provide a competitive analysis of all marketed and pipeline drugs as well as a pipeline analysis of all drugs in development for multiple sclerosis.